SCHEMBL479328

SCHEMBL479328

NCC(F)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.59
HTR2A P28223 3/20 0.59
CHRNB2 P17787 1/20 0.48
CHRNA4 P43681 1/20 0.48
HRH1 P35367 2/20 0.48
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 2/20 0.45
SLC6A2 P23975 1/20 0.45
DPP4 P27487 2/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
F2 P00734 1/20 0.43
GABBR2 O75899 1/20 0.43
GABBR1 Q9UBS5 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10159564 1.00 TAAR1 (0.59) TAAR1HTR2ACHRNB2CHRNA4HRH1
Iodide SCHEMBL28728555 0.97 TAAR1 (0.56) TAAR1HTR2ACHRNB2CHRNA4HRH1
Hydrochloric Acid SCHEMBL4226728 0.97 TAAR1 (0.56) TAAR1HTR2ACHRNB2CHRNA4HRH1
SCHEMBL28587464 0.91 TAAR1 (0.50) TAAR1HTR2ACHRNB2CHRNA4HRH1
SCHEMBL5189954 0.80 HRH1 (0.62) TAAR1HTR2AHRH1SLC6A4SLC6A3
SCHEMBL22620835 0.80 HRH1 (0.62) TAAR1HTR2AHRH1SLC6A4SLC6A3
SCHEMBL4672668 0.80 HRH1 (0.62) TAAR1HTR2AHRH1SLC6A4SLC6A3
SCHEMBL6287110 0.80 TAAR1 (0.48) TAAR1HTR2ACHRNB2CHRNA4HRH1
Hydrochloric Acid SCHEMBL7970943 0.78 HRH1 (0.60) TAAR1HTR2ACHRNB2CHRNA4HRH1
SCHEMBL4126387 0.77 TAAR1 (0.44) TAAR1HTR2ACHRNB2CHRNA4HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120018406-A Fine circuit pattern diffusion inhibitor and preparation method and application method thereof 深圳市板明科技股份有限公司 2025-05-16 CN claimed
CN-119923165-A Solar cell, preparation method thereof, photovoltaic module, system and power utilization device 宁德时代新能源科技股份有限公司 2025-05-02 CN claimed
CN-118853145-A Laser gain medium stable in air for long time and preparation method thereof 电子科技大学长三角研究院(衢州) 2024-10-29 CN claimed
CN-118614160-A Perovskite solar cell, preparation method thereof and power utilization device 宁德时代新能源科技股份有限公司 2024-09-06 CN claimed
CN-117859209-A Perovskite solar cell and preparation method thereof 宁德时代新能源科技股份有限公司 2024-04-09 CN claimed
CN-117442609-A Application of tetrahydrocarbazole derivative in preventing and treating cow mastitis pathogenic bacteria 兰州大学 2024-01-26 CN claimed
CN-117281120-A Application of tetrahydrocarbazole derivative in preventing and controlling agricultural bacterial diseases 兰州大学 2023-12-26 CN claimed
CN-117202748-A Perovskite film and preparation method and application thereof 上海科技大学 2023-12-08 CN claimed
WO-2023216132-A1 PEROVSKITE SOLAR CELL AND PREPARATION METHOD THEREFOR 宁德时代新能源科技股份有限公司 2023-11-16 WO claimed
CN-117015252-A Solar cell with combined action of cesium salt and organic aromatic amine salt and preparation method thereof 电子科技大学 2023-11-07 CN claimed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US claimed
EP-1144403-B1 SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS SEARLE LLC (US) 2004-10-06 EP claimed
US-20040176433-A1 treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis PHARMACIA CORPORATION 2004-09-09 US claimed
US-6617324-B1 Phenyl, cyclohexyl and pyridinyl or pyrimidinyl-substituted G. D. SEARLE & COMPANY 2003-09-09 US claimed
US-6514977-B1 For treating p38 kinase mediated disorders G.D. SEARLE & COMPANY 2003-02-04 US claimed
US-6423713-B1 Substituted pyrazoles as p38 kinase inhibitors G. D. SEARLE & COMPANY 2002-07-23 US claimed
EP-1144403-A1 SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2001-10-17 EP claimed
WO-2000031063-A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2000-06-02 WO claimed
EP-1000055-A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. Searle & Co. (US) 2000-05-17 EP claimed
WO-1998052940-A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE AND CO. (US) 1998-11-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176433-A1 treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis MAPK1, IL1R1, TNF TAAR1 798/4885HTR2A 3942/4885CHRNB2 2978/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 TAAR1 1964/4885HTR2A 4042/4885CHRNB2 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.